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ABSTRACT 57 
Background:High-grade serous ovarian cancer (HGSOC) causes 80% of all OC 58 
deaths. In this setting, the role of cancer stem-like cells (CSCs) is still unclear. In 59 
particular, the evolution of CSC biomarkers from primary (pOC) to recurrent (rOC) 60 
HGSOCs is unknown. Aim of this study was to investigate changes in CD133 and 61 
aldehyde dehydrogenase-1(ALDH1) CSC biomarker expression in pOC and rOC 62 
HGSOCs.  63 
Methods:224 pOC and rOC intra-patient paired tissue samples derived from 112 64 
HGSOC patients(pts) were evaluated for CD133 and ALDH1 expression using IHC. 65 
pOCs and rOCs were compared for CD133 and/or ALDH1 levels. Expression profiles 66 
were also correlated with patients´clinico-pathological and survival data. 67 
Results:49.1%(55/112) and 37.5%(42/112) pOCs were CD133+ and ALDH1+, 68 
respectively. CD133+ and ALDH1+ samples were detected in 33.9%(38/112) and 69 
36.6%(41/112) rOCs. CD133/ALDH1 coexpression was observed in 23.2%(26/112) 70 
and 15.2%(17/112) of pOCs and rOCs, respectively. Pairwise analysis showed a 71 
significant shift of CD133 staining from higher (pOCs) to lower expression levels 72 
(rOCs)(p<0.0001). Furthermore, all CD133+pOC pts were FIGO-stage III/IV 73 
(p<0.0001) and had significantly worse PFI(p=0.04) and OS(p=0.02). On multivariate 74 
analysis, CD133/ALDH1 coexpression in pOCs was identified as independent 75 
prognostic factor for PFI (HR:1.64;95%CI:1.03-2.60;p=0.036) and OS 76 
(HR:1.71;95%CI:1.01-2.88;p=0.045). Analysis on 52 pts with known somatic BRCA 77 
status revealed that BRCA mutations did not influence CSC biomarker expression. 78 
Conclusions:The study showed that CD133/ALDH1 expression impacts HGSOC pts’ 79 
survival and firstly suggests that CSCs might undergo phenotypic change during the 80 
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disease course similarly to non stem-like cancer cells, providing also a first evidence 81 
that there is no correlation between CSCs and BRCA status. 82 
 83 
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INTRODUCTION 88 
Ovarian cancer (OC) remains the most lethal gynecologic malignancy[1]. Advances 89 
in cancer genomics, epigenomics and proteomics has led to the understanding that OC 90 
is a heterogeneous group of different tumors displaying distinct phenotypes and 91 
etiology[2,3]. The current dichotomous OC classification[4,5]groups these tumors in 92 
two distinct categories: Type I (low-grade serous-papillary, low-grade endometrioid, 93 
mucinous and clear-cell carcinomas) and Type II (high-grade serous-papillary, high-94 
grade endometroid, carcinosarcomas and undifferentiated tumors). Type II OCs show 95 
a more aggressive biological behavior, are diagnosed at advanced stage and are 96 
chromosomally highly unstable. Among them, high-grade serous OC (HGSOC) 97 
accounts for around 80% of all OC deaths[3]. The identification of predictive 98 
biomarkers is pivotal for designing new treatment strategies able to reduce HGSOC-99 
related mortality. In this context, the cancer stem-like cell (CSC) theory represents 100 
one model to investigate OC heterogeneity. This hypothesis, supported by increased 101 
evidence acquired in the last decade, proposes that, within OC tissues, a small 102 
population of cells has an increased capacity for self-renewal, tumorigenesis and 103 
differentiation[6]. In multiple experimental studies CSCs showed to increase potential 104 
of tumorigenesis, metastasis/invasion, neoangiogenesis and chemoresistance[7,8]and 105 
have been often correlated with a poor prognosis[9-13]. 106 
Several potential CSC markers have been identified in OC samples[14-15]. Among 107 
them, aldehyde dehydrogenase-1 (ALDH1) and CD133 are currently the best 108 
characterized for ovarian CSCs. Their expression on the cell surface is associated with 109 
increased tumorigenesis and self-renewal capability [16-18]. Nevertheless, the clonal 110 
evolution of CSCs throughout the course of disease, from primary (pOC) to recurrent 111 
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(rOC) OC, has not been elucidated yet and information about the changes in CSC 112 
presence within the tumor after relapse is still lacking. 113 
The aim of this study was to investigate the evolution of CSC biomarkers CD133 and 114 
ALDH1 expression in a large series of paired primary and recurrent HGSOCs. 115 
 116 
MATERIALS AND METHODS 117 
Sample Collection 118 
224 paired samples from 112 HGSOC patients were collected during primary and 119 
secondary tumor debulking. Patients were included consecutively and have been 120 
treated between 1985 and 2013 through primary cytoreduction followed by platinum-121 
based chemotherapy. Patients, retrospectively selected from the OCTIPS (Ovarian 122 
Cancer Therapy–Innovative Models Prolong Survival, Agreement No.279113-2) 123 
Consortium database, were treated for both pOC and rOC in one of the European 124 
Gynecologic Oncology Referral Centers of the following Institutions: Charité 125 
Universitätsmedizin Berlin,Germany; Katholieke Universiteit Leuven,Belgium; 126 
Imperial College, London,UK; University of Edinburgh,UK. 127 
Inclusion criteria were: having experienced at least one OC relapse for which having 128 
been subjected to at least one palliative surgery. Exclusion criterion was: no cancer 129 
tissue available from both pOC and rOC. Approval from each local ethics committee 130 
was obtained (EK207/2003,ML2524,05/Q0406/178,EK130113,06/S1101/16). OC 131 
tissue samples were collected during primary cytoreduction and at the surgery for 132 
relapse. All included samples underwent central histopathological assessment to 133 
confirm the diagnosis of HGSOC and to evaluate the tissue quality and tumor contain. 134 
Immunohistochemistry 135 
Immunohistochemical staining was performed on tissue microarrays (TMAs).  136 
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Slides were deparaffinized in xylol, rehydrated in graded alcohol and boiled in a 137 
pressure cooker for 5 minutes in citrate buffer (pH=6) for ALDH1 staining or in 138 
EDTA (pH=9) for CD133 staining. Mouse anti-human ALDH1-antibody (clone 139 
44;BD Transduction Laboratories,Franklin Lakes, NJ,USA) and mouse anti-human 140 
CD133/1-antibody (AC133 clone;Miltenyi-Biotech, BergischGladbach,Germany) 141 
were diluted 1:500 and incubated on the slides for 60 minutes at room temperature. 142 
Bound antibodies were visualized using DAKO Real Detection System and DAB+ 143 
(3,3′ -diaminobenzidine;DAKO,Glostrup,Denmark) as a chromogen. Finally, the 144 
slides were co-stained with hematoxylin.  145 
CD133 stained samples were assessed basing on the number of stained tumor cells. 146 
Samples were classified as “CD133-negative”(<10% CD133 positive tumor cells) and 147 
“CD133-positive”(>10% CD133-positive tumor cells)[19-20]. 148 
For ALDH1 staining evaluation, as previously published[21-22], the number of 149 
stained tumor cells (0%=0;1-10%=1;11-50%=2;>50%=3) was multiplied with the 150 
intensity of staining(negative=0;weak=1;moderate=2;strong=3), resulting in a 151 
semiquantitive immunoreactivity score(IRS) that ranged from 0 to 9. For further 152 
analysis, samples were classified “ALDH1-negative”, for absent or weak focal 153 
staining(IRS=0-1), or “ALDH1-positive”, for ALDH1-high tumor expression(IRS=2-154 
9). 155 
All samples were evaluated independently by two co-authors (IR and SDE). 156 
Clinical Data and Follow-up 157 
Patients’ clinical data and information on 52 patients’ germline and/or somatic BRCA 158 
status were retrieved from OCTIPS Consortium database[23-24]. Platinum-159 
resistance and platinum-sensitivity were defined, according to GCIG, as relapse 160 
occurring before or after six months following the last platinum-based chemotherapy, 161 
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respectively[25]. Recurrence was defined basing on RECIST Criteria[26]. A sole 162 
CA125 serum elevation was not considered relapse[27]. 163 
Statistical Analysis 164 
Statistical analysis was performed using SPSS version 22.0(SPSS Inc, Chicago, IL, 165 
USA). To assess the difference between pOCs and rOCs in terms of biomarker 166 
expression, the correlation test (Spearman coefficient, 2-tailed) and the “Wilcoxon 167 
signed rank” non-parametric test for related samples were applied. Correlation of 168 
CD133 and ALDH1 tumor expression with patients’ clinico-pathological categorical 169 
data was assessed using the Fisher’s exact test. Patients’ progression-free 170 
interval(PFI), progression-free survival (PFS) and overall survival(OS) were 171 
determined by Kaplan–Meier analysis (Log-Rank test).PFI represented the time 172 
interval from the last adjuvant chemotherapy to relapse, whereas progression-free 173 
survival (PFS) was the time interval between first recurrence diagnosis and tumor 174 
progression. For univariate and multivariate survival analyses, the Cox regression 175 
model was used. Multivariable models were performed among variables reporting a 176 
p-value≤0.1 in univariate analysis. P values≤0.05 were considered statistically 177 
significant. 178 
 179 
RESULTS 180 
Primary and recurrent intra-patient paired tumor samples derived from 112 HGSOC 181 
patients were analyzed for CD133 and ALDH1 expression. Patients’ characteristics 182 
are listed in Table 1.  183 
Immunohistochemistry staining showed that ALDH1 and CD133 proteins were 184 
localized to the cytoplasm(Fig1,Fig.3). 185 
 186 
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 187 
CD133 expression. 188 
CD133-positive (CD133+) staining was significantly more frequent among 189 
pOCs[55/112(49.1%)] compared to rOCs[38/112(33.9%)], p=0.030(Fisher’s exact 190 
test,Fig.1a,1c). Investigation of sequential changes in CD133+ expression in paired 191 
tumors, with a correlation test (Spearman coefficient) between pOCs and rOCs, 192 
demonstrated a significant correlation (p=0.001,Spearman coefficient 0.306).  193 
Furthermore, pairwise testing revealed a significant shift from higher frequency of 194 
CD133+ cells in pOCs to lower levels in the paired recurrent samples (p<0.0001, 195 
Wilcoxon test;Fig.2), thus indicating significantly higher rates of CD133+ cells in 196 
pOCs compared to rOCs.  197 
ALDH1 expression. 198 
Distribution of ALDH1 IRS in pOCs and rOCs is shown in Fig.3a,3d. ALDH-1 199 
positive tumors were found in 37.5%(42/112) and 36.6%(41/112) of primary and 200 
recurrent samples, respectively (p=1,Fisher’s exact test,Fig.3b,3e). A trend for 201 
significant correlation between pOCs and rOCs ALDH1-expression levels was seen 202 
(p=0.059,Spearman coefficient 0.179). Pairwise analysis showed no tendency towards 203 
a change of IRS values to higher or lower levels in recurrences (p=0.988,Wilcoxon 204 
test;Fig.4).  205 
CD133/ALDH1 co-expression. 206 
Co-expression of both CSCs biomarkers was detected in 23.2%(26/112) of pOCs and 207 
in 15.2%(17/112) of rOCs(p=0.174,Fisher’s exact test). Among 26 patients reporting 208 
CD133/ALDH1 co-expression in pOCs, 22(84.6%) lost this pathological 209 
characteristic in relapse situation. Of the 17 patients presenting biomarker co-210 
expression in rOC, 13(76.5%) showed no co-expression in pOC. Consequently, 4/112 211 
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patients (3.6%) showed CD133/ALDH1 co-expression in both pOC and rOC: two of 212 
them were platinum-resistant and two were platinum-sensitive. 213 
CSCs biomarkers and clinico-pathological factors  214 
We analyzed the correlation of ALDH1 and/or CD133 tumor expression patterns in 215 
pOCs with patients´ clinico-pathological characteristics. All primary CD133+ patients 216 
were diagnosed at FIGO III/IV stage (p=0.006). No correlation was observed between 217 
other clinico-pathological factors and ALDH1 and/or CD133 tumor 218 
expression(Tab.2).  219 
Survival 220 
CD133 positivity in pOCs was significantly associated with poor PFI and OS 221 
(Fig.5a,5b). In particular, CD133+ and CD133- patients reported median OS of 51 and 222 
71 months (HR:1.713;95%CI:1.076-2.727;p=0.02) and median PFI of 9 and 17 223 
months (HR:1.477;95%CI:1.006-2.170;p=0.04). PFS after recurrence was not 224 
significantly different (p=0.868,Fig.5c) between patients with CD133+ and CD133- 225 
or between (p=0.252,Fig.5f) patients with ALDH1+ and ALDH1rOC. 226 
Median OS for ALDH1+ and ALDH1- patients was 52 and 64 months, respectively 227 
(p=0.402) and median PFI-1 was 9 and 17 months, respectively (p=0.199)(Fig.5d,5e).  228 
ALDH1/CD133 co-expression in pOCs was found to significantly affect HGSOC 229 
patients’ outcome. A significant decrease in OS and PFI has been found in patients 230 
co-expressing ALDH1/CD133 in primary tissue (46 and 9 months, respectively) 231 
compared to patients without biomarker co-expression (68 and 17 months, 232 
respectively) (p=0.019,Fig.5g;p=0.015,Fig.5h). No significant difference in PFS after 233 
relapse was observed between patients who reported CD133/ALDH1 co-expression or 234 
no co-expression in rOC(p=0.898,Fig.5i). 235 
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On multivariate analysis, the co-expression of ALDH1 and CD133 in pOC, rather 236 
than the single expression of one biomarker, was identified to be an independent 237 
prognostic factor for both PFI (HR:1.638;95%CI:1.033-2.598;p=0.036) and OS 238 
(HR:1.707;95%CI:1.012-2.881;p=0.045) in HGSOC(Tab.3,4). 239 
Outliers’ sub-analysis 240 
“Outliers” were considered patients for whom the highest difference between pOC 241 
and rOC could be detected in CD133+cell rate. Three patients were identified: two 242 
reported a difference in CD133+cell rate of -90%(from 90% of CD133+cells at pOC 243 
to 0% at rOC); the first one was a platinum-resistant patient with PFI of 2 months and 244 
OS of 14 months; the second one was a platinum-sensitive patient with PFI of 7 245 
months and OS of 9 months. The third patient showed a difference in CD133+cell 246 
rate of +70%(from 0% of CD133+ at pOC cells to 70% in rOC) with PFI of 15 247 
months (platinum-sensitive) and OS of 44 months. 248 
CSC biomarker expression and BRCA status 249 
In order to investigate if BRCA mutations could influence CSC biomarker expression, 250 
a subgroup analysis was carried out among 52 patients, whose germline and/or 251 
somatic BRCA status (assessed on pOC and rOC) was available [24]. 40.4% of tested 252 
patients (21/52) had a somatic BRCA mutation in both pOCs and rOCs: 16/52(30.8%) 253 
were BRCA1-mutated (mBRCA1) and 5/52(9.6%) were BRCA2-mutated 254 
(mBRCA2)(Tab.5). 255 
No significant difference in CD133 and/or ALDH1 expression was found between 256 
BRCA-wild type (BRCA-WT) and BRCA-mutant (mBRCA1/2) tumors(Tab.6). 257 
Among BRCA-WT patients, no correlation between pOCs and rOCs in CD133+ 258 
expression was observed (p=0.088,Spearman coefficient 0.312). Furthermore, in 259 
accordance with results observed in the whole population, paired testing revealed a 260 
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significant shift from higher levels in pOCs to lower levels in the rOCs 261 
(p<0.0001,Wilcoxon test;Fig.6a). In contrast, among mBRCA1/2 patients, no 262 
correlation between pOCs and rOCs (p=0.493,Spearman coefficient 0.158), or a 263 
tendency towards a change in CD133+ expression was observed (p=0.167,Wilcoxon 264 
test;Fig.6b).   265 
Regarding ALDH1 expression, among BRCA-WT patients no correlation between 266 
pOCs and rOCs in ADH1 IRS was found (p=0.986,Spearman coefficient 0.003), as 267 
well as no change in paired testing (p=0.895,Wilcoxon test;Fig.7a); also for 268 
mBRCA1/2 patients no difference was observed in ALDH1-IRS between primary and 269 
recurrent patients (p=0.410,Spearman coefficient 0.190;p=0.385,Wilcoxon 270 
test;Fig.7b). 271 
Among BRCA-WT patients, only 1/31 patient (3.2%) showed CD133/ALDH1 co-272 
expression in both pOCs and rOCs. In 3/31(9.7%) patients the co-expression was 273 
evidenced in rOCs but not in pOCs. 90% of patients (9/10) reporting CD133/ALDH1 274 
co-expression in pOC lost biomarker co-expression at tumor relapse. 275 
Also for mBRCA1/2 patients, only 1/21(4.8%) patient showed CD133/ALDH1 co-276 
expression in both pOC and rOC. Two patients (9.5%) had co-expression at recurrent 277 
rather than at primary disease. The difference between BRCA-WT and mBRCA1/2 278 
patients in terms of co-expression loss at rOC was not significant (4/5 vs 9/10,p=1, 279 
Fisher’s exact test).  280 
Considering patients who were CD133+ and/or ALDH1+ at pOC, no significant 281 
difference could be detected in PFI and OS among BRCA-WT vs mBRCA1/2 282 
cases(Fig.8).  283 
 284 
DISCUSSION  285 
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In the Era of Precision Medicine, huge steps have been taken in the understanding of 286 
HGSOC biology. In this tumor setting, the role of CSC and its clonal evolution during 287 
subsequent disease relapse has been relatively unexplored. 288 
This study investigated the changes in CSC biomarkers CD133 and ALDH1 289 
expression in primary and recurrent HGSOCs and showed that CD133+CSCs are 290 
significantly more represented in pOCs rather than rOCs, whereas no significant 291 
changes in terms of ALDH1 expression levels occurred at disease relapse. 292 
Furthermore, CD133 positivity in pOCs significantly correlates with poor survival, 293 
while co-expression of both CD133 and ALDH1 in primary samples independently 294 
predicted poor PFI and OS in HGSOC patients. 295 
In 2015, Zhou published a meta-analysis[28], which investigated the prognostic value 296 
of immunohistochemical CD133 expression in OC. Pooled data derived from 1050 297 
patients from 8 studies showed that CD133 positivity significantly correlates with 298 
advanced FIGO stage at diagnosis and with worse OS, in accordance with our 299 
findings, although our population was restricted to HGSOC. 300 
Other recent meta-analysis demonstrated that also ALDH1 is a promising prognostic 301 
biomarker for breast[9], head/neck[10], lung[11]and colorectal cancer[12] but its 302 
predictive or prognostic role in OC is still controversial[13,29-31]. In contrast to 303 
CD133, ALDH1 expression is usually low or negative in serous OC compared to 304 
other cancer histotype and more frequent in low FIGO stage tumors[13,29].  305 
Previously, Liebscher[21] investigated the prognostic impact of ALDH1 expression 306 
in a homogeneous group of primary HGSOC patients and demonstrated that ALDH1 307 
was an independent prognostic factor for OS. These results differ from our findings, 308 
since in our population ALDH1 did not have an impact on patients’ survival. 309 
Nevertheless, in Liebscher’s population the frequency of FIGO Stage I-II cases was 310 
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higher than in our population (11.5% vs 7.2%), while the number of optimally 311 
cytoreduced patients was lower (66.3% vs 80.4%). 312 
Silva[32] showed that the co-expression of CD133 and ALDH1 correlated with  313 
significant worse PFI and OS in a small cohort of 56 ovarian cancer patients. These 314 
results were in accordance with our findings in a larger HGSOC population. 315 
To our knowledge, this is the first study analyzing the evolution of CSC markers in 316 
the largest cohort of primary and recurrent HGSOC patients. Furthermore, the 317 
subanalysis on patients with known BRCA status increases the value of the findings 318 
by taking into consideration the genetic influence of BRCA status on patients’ 319 
survival[33-34]and provides a first evidence of the correlation between tumor-320 
initiating cells and homologous recombination deficieny. Limitation of the study was 321 
the lack of information regarding BRCA1/2 status on all enrolled patients. The 322 
analysis on a cohort of 52 patients could not provide definitive conclusions for this 323 
issue.  324 
Interestingly, we observed that 84.6% of our patients’ cohort reporting 325 
CD133/ALDH1 co-expression in pOC lost this pathological characteristic at relapse. 326 
Nevertheless, while CSC biomarker expression is significantly correlated with poor 327 
prognosis, it is enigmatic why in a recurrent setting, which represents a more 328 
aggressive step of the disease compared to primary disease, CSCs are less frequently 329 
encountered. Theoretically, CSCs were expected to be much more frequent in rOC 330 
than in the pOC. We hypothesize that the reduction in CSC biomarker expression 331 
does not represent a reduction in CSC number within the tumor sample, but might be 332 
the result of cellular reprogramming occurring in the CSC itself, which might lead to 333 
the loss of CSC biomarker expression. Studies on this issue are still lacking.                           334 
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This study shows that CD133 and ALDH1 as biomarkers can have influence on 335 
HGSOC patients’ survival and for the first time suggests that they might be caused by 336 
a phenotypical change during the course of the disease similarly to non stem-like 337 
cancer cells. However, the need for recurrent tumor tissue to be analyzed implied that 338 
this cohort of samples might be not the most representative one for ovarian cancer 339 
patients, due to the fact that most of patients had a platinum sensitive relapse, and 340 
surgical approach at relapse was feasible. For this reason, general conclusion for the 341 
whole recurrent ovarian cancer setting cannot currently be drawn.  342 
Another limitation of the study is that these biomarkers, in particular ALDH1, are 343 
broadly expressed, not only by CSCs. The identification of CSC is actually sure only 344 
based on the capacity to build spheroids, on tumor xenograft assay and on serial 345 
transplantation assay, which require fresh tumor tissue. Nevertheless, IHC allowed to 346 
analyze a large cohort of paired tumor tissues and to observe that there is a change in 347 
CSC–associated biomarker expression between primary and relapse disease. 348 
Further investigations on larger cohort of paired pOC and rOC samples are warranted, 349 
potentially expanding the scope with inclusion of further candidate CSC markers and 350 
with evaluation of CSCs behavior following neoadjuvant chemotherapy[31,35-36], 351 
in order to reduce mortality of one of the most deadly malignancies of our time.  352 
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	PARAMETER  
PATIENTS (n.) 112 
AGE 
Median (range) 
 
56y (33-77y) 
FIGO STAGE (%) 
- I 
- II 
- III 
- IV 
 
2 (1.8%) 
6 (5.4%) 
93 (83%) 
11 (9.8%) 
RESIDUAL TUMOR AFTER PRIMARY DEBULKING SURGERY: 
- No residual tumor 
- Residual Tumor 
 
90 (80.4%) 
22 (19.6%) 
PLATINUM SENSITIVITY STATUS AFTER PRIMARY TREATMENT 
      -   Platinum sensitive 
- Platinum resistant 
- Missing 
 
90 (80.4%) 
18 (16.1%) 
4 (3.5%) 
PLATINUM SENSITIVITY STATUS AFTER TREATMENT FOR DISEASE RELAPSE 
- Platinum sensitive 
- Platinum resistant 
- Missing 
 
59 (52.7%) 
12 (10.7%) 
41(36.6%) 
Table 1 
Table 2 
Clinico-pathological 
factors 
Total 
N°           CD133            ALDH1 CD133 and ALDH1 coexpression 
  
Positive 
(%) 
Negative 
(%) P 
Positive 
(%) 
Negative 
(%) P 
Positive 
(%) 
Negative 
(%) P 
Patients’ Age 
< 56y 
≥ 56y 
 
54 
58 
 
27 (50%) 
28 (48%) 
 
27 (50%) 
30 (52%) 
 
0.855 
 
18 (33%) 
25 (43%) 
 
36 (67%) 
33 (57%) 
 
0.288 
 
11 (20%) 
15 (26%) 
 
43 (80%) 
43 (74%) 
 
0.492 
FIGO STAGE 
I/II 
III/IV 
 
8 
104 
 
0 
55 (53%) 
 
8 (100%) 
49 (47%) 
 
0.006 
 
3 (38%) 
40 (39%) 
 
5 (62%) 
64 (61%) 
 
1.000 
 
0 
26 (25%) 
 
8 (100%) 
78 (75%) 
 
0.194 
RESIDUAL TUMOR 
AFTER FIRST 
CYTOREDUCTIVE 
SURGERY 
No residual 
Any residual 
 
 
 
 
90 
22 
 
 
 
 
42 (47%) 
13 (59%) 
 
 
 
 
48 (53%) 
9 (41%) 
 
 
 
 
0.346 
 
 
 
 
35 (39%) 
8 (36%) 
 
 
 
 
55 (61%) 
14 (64%) 
 
 
 
 
1.000 
 
 
 
 
20 (22%) 
6 (27%) 
 
 
 
 
70 (78%) 
16 (73%) 
 
 
 
 
0.586 
PLATINUM 
SENSITIVITY 
STATUS AFTER 
PRIMARY 
TREATMENT 
Platinum sensitive 
Platinum resistant 
 
 
 
 
 
90 
18 
 
 
 
 
 
43 (48%) 
7 (39%) 
 
 
 
 
 
47 (52%) 
11 (61%) 
 
 
 
 
 
0.439 
 
 
 
 
 
33 (37%) 
9 (50%) 
 
 
 
 
 
57 (63%) 
9 (50%) 
 
 
 
 
 
0.303 
 
 
 
 
 
19 (21%) 
6 (33%) 
 
 
 
 
 
71 (79%) 
12 (67%) 
 
 
 
 
 
0.357 
 
Table 3 
PROGRESSION FREE INTERVAL 
 UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS 
  HR (95% CI)                  P HR (95% CI)                 P 
Age  1.003 (0.983-1.024) 0.774
FIGO Stage (III/IV vs I/II) 
 
2.019 (0.907-4.496) 0.085  1.856 (0.826-4.169) 0.134 
Residual Tumor 
(any residual vs no residual) 
 
1.026 (0.625-1.684) 0.919    
CD133/ALDH1 coexpression
(positive vs negative) 
 
1.729 (1.093-2.733) 0.019  1.638 (1.033-2.598) 0.036 
 
Table 4 
OVERALL SURVIVAL 
  UNIVARIATE ANALYSIS        MULTIVARIATE ANALYSIS 
  HR (95% CI)               P HR (95% CI)                  P 
Age  1.011 (0.985-1.038) 0.404 
FIGO Stage (III/IV vs I/II)  1.465 (0.533-4.020) 0.459 
Residual Tumor 
(any residual vs no residual) 
 1.632 (0.973-2.736) 0.063 1.272 (0.725-2.231) 0.401 
Platinum sensitivity status 
after primary treatment 
(platinum resistant vs 
platinum sensitive) 
 
3.394 (1.927-5.978) <0.001 2.907 (1.594-5.302) <0.001 
CD133/ALDH1 coexpression 
(positive vs negative) 
 
1.799 (1.089-2.971) 0.022 1.707 (1.012-2.881) 0.045 
 
Table 5 
PATIENT ID GERMLINE BRCA STATUS SOMATIC BRCA STATUS –  PRIMARY TUMOR 
SOMATIC BRCA STATUS – 
RECURRENT TUMOR 
B001 mBRCA1 mBRCA1 mBRCA1 
B002 WT WT WT 
B003 WT WT WT 
B006 N/A WT WT 
B007 N/A WT WT 
B009 N/A WT WT 
B012 N/A WT WT 
B015 N/A WT WT 
B019 WT mBRCA2 mBRCA2 
B021 N/A WT WT 
B022 N/A WT WT 
B024 mBRCA1 mBRCA1 mBRCA1 
B025 N/A WT WT 
B026 N/A WT WT 
B028 mBRCA1 mBRCA1 mBRCA1 
B029 mBRCA1 mBRCA1 mBRCA1 
B030 N/A WT WT 
B032 WT WT WT 
B037 N/A WT WT 
B041 mBRCA1 mBRCA1 mBRCA1 
B044 N/A WT WT 
B045 N/A mBRCA1 mBRCA1 
B048 WT WT WT 
B050 WT WT WT 
B051 N/A mBRCA2 mBRCA2 
B052 WT WT WT 
B053 N/A WT WT 
B054 N/A WT WT 
B062 N/A WT WT 
B063 N/A mBRCA2 mBRCA2 
B065 WT WT WT 
B068 N/A mBRCA1 mBRCA1 
B069 N/A WT WT 
B071 N/A mBRCA1 mBRCA1 
B077 mBRCA2 mBRCA2 mBRCA2 
B080 mBRCA2 mBRCA2 mBRCA2 
B081 WT mBRCA1 mBRCA1 
B082 N/A mBRCA1 mBRCA1 
B085 N/A mBRCA1 mBRCA1 
B087 mBRCA1 mBRCA1 mBRCA1 
B088 N/A WT WT 
B090 N/A mBRCA1 mBRCA1 
B093 N/A WT WT 
B094 N/A mBRCA1 mBRCA1 
B097 N/A mBRCA1 mBRCA1 
B098 N/A WT WT 
B099 N/A WT WT 
B100 N/A WT WT 
L007 WT WT WT 
L010 WT WT WT 
L017 WT WT WT 
L020 mBRCA1 mBRCA1 mBRCA1 
Table 6 
BRCA status Total N°               CD133             ALDH1 
CD133 and ALDH1 
coexpression 
  
Positive 
(%) 
Negative 
(%) P 
Positive 
(%) 
Negative 
(%) P 
Positive 
(%) 
Negative 
(%) P 
BRCA-WT 
mBRCA1/2 
31 
21 
21 (68%) 
13 (62%) 
10 (32%) 
8 (38%) 0.769 
13 (42%) 
7 (33%) 
18 (58%) 
14 (67%) 0.575 
10 (32%) 
5 (24%) 
21 (68%) 
16 (76%) 0.551 
 
